Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy
- PMID: 26328203
- PMCID: PMC4548661
- DOI: 10.5152/tud.2015.65624
Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy
Abstract
Objective: This study was conducted to research the factors determining biochemical recurrence (BCR) in low-risk localized prostate cancer patients who underwent radical prostatectomy (RP).
Materials and methods: We retrospectively analyzed the data of 504 patients who had undergone RP between 2003 and 2013 at our clinic. One hundred and fifty-two patients who underwent RP for low-risk prostate cancer were included in the study.
Results: The mean follow-up period for patients was 58.7 (21-229) months. The mean age of the patients was 63.7±7.2 years (49-79). The mean prostate specific antigen (PSA) value was 5.25±4.22 ng/mL (3.58-9.45). The BCR rate after the operation was 25% (38/152). In the univariate analysis, recurrence determining factors were shown to include extracapsular involvement (ECI) (p=0.004), capsular invasion (CI) (p=0.001), age (p=0.014), and tumor size (p=0.006). However, only CI was found to be significant in multivariate analysis (p=0.001).
Conclusion: Capsular invasion is an independent risk factor in low-risk prostate cancer patients who underwent RP for BCR.
Keywords: Biochemical recurrence; low-risk; radical prostatectomy.
Similar articles
-
The factors predicting biochemical recurrence in patients with radical prostatectomy.Arch Ital Urol Androl. 2016 Jan 14;87(4):270-5. doi: 10.4081/aiua.2015.4.270. Arch Ital Urol Androl. 2016. PMID: 26766796
-
Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):714-24. doi: 10.1016/j.ijrobp.2004.06.018. Int J Radiat Oncol Biol Phys. 2005. PMID: 15708249
-
Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results.Eur Radiol. 2016 Aug;26(8):2502-9. doi: 10.1007/s00330-015-4077-5. Epub 2015 Nov 11. Eur Radiol. 2016. PMID: 26560721
-
[Comparison of the Biochemical Recurrence risk between Radical Prostatectomy and Brachytherapy in the treatment of low- and intermediate-risk prostate cancer].Arch Esp Urol. 2015 Oct;68(8):655-60. Arch Esp Urol. 2015. PMID: 26437328 Spanish.
-
Radical prostatectomy and positive surgical margins: relationship with prostate cancer outcome.Int Braz J Urol. 2014 May-Jun;40(3):306-15. doi: 10.1590/S1677-5538.IBJU.2014.03.03. Int Braz J Urol. 2014. PMID: 25010296
Cited by
-
Analysis of outcomes after non-contour-based dose painting of dominant intra-epithelial lesion in intra-operative low-dose rate brachytherapy.Heliyon. 2020 Jun 7;6(6):e04092. doi: 10.1016/j.heliyon.2020.e04092. eCollection 2020 Jun. Heliyon. 2020. PMID: 32548323 Free PMC article.
-
Prognostic significance of a novel indicator (PSApostd3/PSApre) for PSA recurrence in patients after radical prostatectomy.Cancer Manag Res. 2019 Jun 25;11:5777-5783. doi: 10.2147/CMAR.S197521. eCollection 2019. Cancer Manag Res. 2019. PMID: 31417316 Free PMC article.
-
Prostate Cancer-PET Imaging Update.Cancers (Basel). 2023 Jan 28;15(3):796. doi: 10.3390/cancers15030796. Cancers (Basel). 2023. PMID: 36765754 Free PMC article. Review.
-
Proton therapy- the modality of choice for future radiation therapy management of Prostate Cancer?Tech Innov Patient Support Radiat Oncol. 2019 Oct 11;11:1-13. doi: 10.1016/j.tipsro.2019.08.001. eCollection 2019 Sep. Tech Innov Patient Support Radiat Oncol. 2019. PMID: 32095544 Free PMC article. Review.
References
-
- Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol. 2005;16:481–8. - PubMed
-
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statics, 2006. CA Cancer J Clin. 2006;56:106–30. http://dx.doi.org/10.1093/annonc/mdi098. - DOI - PubMed
-
- Grossfeld GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC, et al. Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. J Urol. 2000;163:1171–7. http://dx.doi.org/10.3322/canjclin.56.2.106. - DOI - PubMed
-
- Zanatta DA, Andrade RJ, Pacagnan EF, München LW, Assumpção RA, Mercante VC, et al. Early stage prostate cancer: biochemical recurrenc eafter treatment. Int Braz J Urol. 2014;40:137–45. http://dx.doi.org/10.1016/S0022-5347(05)67716-6. - DOI - PubMed
-
- Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract. 2004;58:382–90. http://dx.doi.org/10.1590/S1677-5538.IBJU.2014.02.02. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous